GlobeNewswire
-
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
16/11/2026 -
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
16/11/2026 -
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
16/11/2026 -
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
16/11/2026 -
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
16/11/2026 -
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
16/11/2026 -
Former Cross Country Healthcare CEO Bill Grubbs Takes Expanded Role as LUKE Executive Chairman
16/11/2026 -
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
16/11/2026 -
NewGen Provides Business Update
16/11/2026 -
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
16/11/2026 -
Lumexa Imaging Opens Three New Imaging Centers in November
16/11/2026 -
GT Biopharma Reports Third Quarter 2026 Financial Results
16/11/2026 -
ToltIQ Chooses ABBYY for Parsing Complex Deal Documents
16/11/2026 -
Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
J-Star Holding Successfully Completes Advanced Composite Skin-to-Structure Welding Trials Built on Proprietary Manufacturing Technology
16/11/2026 -
Noema Pharma Receives FDA Orphan Drug Designation for Basimglurant for the Treatment of Trigeminal Neuralgia
16/11/2026 -
Apptly Health Technologies Announces Strategic Partnership with BioTrax AI to Bring Precision Longevity Tools to Its Physician Network
16/11/2026 -
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
16/11/2026
Pages